Asimov introduces its AI-driven 4th generation CHO Edge System with increased titre guarantee

• Enables unique vector and process optimizations for different molecules to increase the likelihood of high titre clonal cell lines.
• Asimov now guarantees titres of 5 g/L for IgG monoclonal antibodies, as part of its Cell Line Development (CLD) Service

Boston, Massachusetts, 30 July 2024: Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of its fourth generation CHO Edge System. With an increased typical titre range of 5-11 g/L across modalities before any upstream process optimization, the new system has been developed to optimize expression across a breadth of biologic architectures and increase the likelihood of high titre cell lines.

The system’s improved robustness has allowed Asimov to increase its minimum CLD titre guarantee for IgG monoclonal antibodies to 5 g/L. If the lead clone does not hit this benchmark, it is still transferred to the partner, but the service fee and all commercial use license fees are waived.

The 4th generation CHO Edge System updates expression vector architectures, genetic parts selection, and process methodologies. In addition, the new system incorporates a suite of AI models to predict signal peptide cleavage, RNA splicing, and upstream process optimization. Customers can access these advanced capabilities by licensing the CHO Edge System or as part of Asimov’s Cell Line Development Service

Alec Nielsen, co-founder and CEO of Asimov said: “Our 4th generation CHO Edge System incorporates learnings from a wide range of molecules, and an array of proprietary data-driven AI models. We have upgraded the vector architectures, genetic parts selection, and predictive modeling across multiple biological processes. While we always target titers in excess of 10 g/L in our CLD process, we can now guarantee a minimum of 5 g/L for IgG molecules. By offering a titer guarantee, we aim to set a new standard for cell line development in the industry and redefine the expectations of therapeutic developers.”

The CHO Edge System incorporates a GMP-banked CHO-K1 GS knock-out host (or a GS-Fut8 double knockout), a hyperactive transposase, a library of >1000 characterized genetic parts and advanced computational models. Asimov reliably generates stable cell lines with high titre and product quality by using the CHO Edge System to optimize the expression vector across modalities.

For more information about Asimov and the CHO Edge System, please visit https://www.asimov.com/cho

About Asimov
Asimov’s mission is to advance humanity’s ability to design living systems, enabling biotechnologies with outsized societal benefit. The company is developing a synthetic biology platform – from cells to software – to design and manufacture next-generation therapeutics, including biologics, cell/gene therapies, and RNA through a combination of products, services, and collaborations. Founded by bioengineers from MIT and Boston University and headquartered in Boston, the company has raised over $200 million from top institutional investors including Andreessen Horowitz, CPP Investments, Horizons Ventures, and Fidelity Management & Research Company. For more information, visit www.asimov.com.